EPCLUSA has a Boxed Warning on the risk of HBV reactivation in HCV/HBV coinfected patients. Hepatitis B (HBV) reactivation has been reported in HCV/HBV coinfected patients who were undergoing or completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Patients should be tested for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. Learn more about the Boxed Warning on the risk of HBV reactivation and EPCLUSA safety.